Plastic Norepinephrine Formulation With Low Surface Exposure Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Norepinephrine formulations are prone to degradation, particularly due to oxidation and the formation of impurities like 1,2,3,4-tetrahydroisoquinoline-4,6,7-triol, especially when stored in plastic containers.

Innovation Solution

The formulation is contained in a plastic container with a controlled surface area to volume ratio of less than 3.0 cm−1, minimizing the formation of 1,2,3,4-tetrahydroisoquinoline-4,6,7-triol impurity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If norepinephrine is stored in plastic containers, then convenience of storage and transport is improved, but degradation into impurities like 1,2,3,4-tetrahydroisoquinoline-4,6,7-triol occurs

Engineering Contradiction:
Improveconvenience of storage and transportVSAvoidchemical stability of norepinephrine
Core Design Contradiction:
Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent changes the geometric parameters of the container by controlling the surface area to volume ratio to be less than 3.0 cm⁻1. This parameter modification reduces the relative surface area exposed to the norepinephrine solution, thereby minimizing oxidation and degradation reactions while maintaining the convenience of plastic container storage.

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If the surface area of the plastic container is reduced, then impurity formation is minimized, but the container size is constrained

Engineering Contradiction:
Improveminimization of impurity formationVSAvoidcontainer volume
Core Design Contradiction:
Stability of the object's compositionVSVolume of moving object

Solution Approach 1:

The patent establishes a specific parameter range for the surface area to volume ratio (less than 3.0 cm⁻1) that balances impurity minimization with practical container sizing. This allows for extended storage periods while maintaining acceptable container dimensions for clinical use.

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If norepinephrine is stored at higher concentrations, then storage stability is improved, but the formulation becomes more prone to degradation

Engineering Contradiction:
Improvestorage stabilityVSAvoiddegradation susceptibility
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent changes the concentration parameter of the norepinephrine formulation to low concentrations (0.01-0.1 mg/ml), which counterintuitively improves stability by reducing the driving force for oxidation reactions, while the container geometry parameter (surface area to volume ratio < 3.0 cm⁻1) further suppresses degradation pathways.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solution enhances the stability of norepinephrine formulations, allowing them to be stored for extended periods with minimal impurity formation, maintaining effectiveness for administration.

Implementation Method 1

Norepinephrine is sensitive to oxidation and will normally degrade into several oxidation-related impurities. Norepinephrine is therefore often protected from oxygen by degassing the solutions used for producing the norepinephrine formulation and/or including an antioxidant in the final formulation.

Methodology Applied
Scientific EffectOxidation: Oxidation

Data Source

PatentUS20260021060A1Ready-to-administer product comprising a norepinephrine formulation
Publication Date: 2026.01.22 HIKMA PHARMACEUTICALS USA INC
  • US20260021060A1 patent drawing
  • US20260021060A1 patent drawing
  • US20260021060A1 patent drawing

AI summary

Described herein are ready-to-administer products comprising liquid norepinephrine formulations contained in a flexible plastic container